Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesDyne Therapeutics Inc

Dyne Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
17.99 USD 0.07 ( 0.39%)
Last update at 2026-11-11T21:00:00Z
VOLUME
1907808
Market Cap
1344.68M

Momentum Score

…

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
17.84
Low
18.31
High
52 Week Price Range
6.36
Low
47.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Dyne Therapeutics is a clinical-stage biotechnology company developing targeted genetic medicines for rare neuromuscular diseases using a proprietary delivery platform intended to improve tissue targeting of oligonucleotide therapeutics. Long-term growth drivers include advancement of its pipeline through clinical trials, potential regulatory approvals and commercialization, and platform expansion or partnering that could broaden addressable indications and may appeal to investors seeking exposure to delivery-focused genetic therapies. Investors should monitor development milestones and financing needs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
17.92
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-64.01%
Net Debt
-411.46M
ROCE
-26.60%
Diluted EPS TTM
-3.61

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -168.10M -149.29M -59.44M -14.86M -4.81M
Net income -165.24M -149.28M -58.74M -13.54M -4.81M
Selling general administrative 28.20M 28.72M 13.45M 2.79M 0.52M
Reconciled depreciation 1.68M 1.09M 0.70M 0.27M 0.02M
Ebit -172.65M -150.03M -59.35M -13.83M -4.81M
Ebitda -170.96M -148.20M -58.65M -14.59M -4.79M
Depreciation and amortization 1.68M 1.82M 0.70M -0.76M 0.02M
Operating income -170.96M -150.03M -58.65M -13.83M -4.79M
Other operating expenses 170.96M 150.03M 58.65M 13.83M 4.79M
Interest expense 2.92M 0.74M 0.40M 0.29M 0.01M
Interest income 2.92M 0.74M 0.06M 0.29M 0.01M
Net interest income 2.92M 0.74M -0.34M 0.29M 0.01M
Income tax expense -2.86M -0.01M -0.70M -1.32M -0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 170.96M 150.03M 58.65M 13.83M 4.79M
Total other income expense net 2.86M 0.73M -0.79M -1.03M -0.02M
Net income from continuing ops -168.10M -149.29M -59.44M -14.86M -4.81M
Net income applicable to common shares -168.10M -149.29M -59.44M -14.86M -4.81M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 691.23M 165.08M 306.32M 425.66M 353.33M
Other current assets 17.01M 6.28M 9.58M 5.82M 3.77M
Total liab 61.40M 73.79M 53.96M 57.47M 10.97M
Total stockholder equity 629.84M 91.29M 252.36M 368.20M 342.37M
Other current liab 30.85M 23.44M 18.22M 20.80M 7.53M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -949.93M -632.51M -396.57M -228.47M -79.18M
Other assets - 0.00M 2.32M 2.31M 2.30M
Cash 435.45M 121.63M 172.15M 200.82M 300.85M
Total current liabilities 42.26M 51.09M 28.09M 28.72M 10.97M
Net debt -411.46M -94.21M -141.66M -168.19M -300.85M
Short term debt 4.85M 4.72M 4.61M 3.89M -
Short long term debt total 23.99M 27.41M 30.48M 32.64M -
Other stockholder equity 1579.75M 723.80M 649.50M 596.93M 421.57M
Property plant equipment - - 38.41M 40.96M 1.95M
Total current assets 659.28M 129.38M 256.01M 382.39M 345.31M
Net tangible assets - - 252.36M 368.20M 342.37M
Short term investments 206.82M 1.47M 83.86M 175.75M 44.46M
Accounts payable 6.56M 22.94M 5.26M 4.03M 3.44M
Accumulated other comprehensive income 0.01M - -0.57M -0.27M -0.03M
Common stock total equity - - - - 0.01M
Non currrent assets other 1.94M -0.00M 11.90M 2.31M 6.07M
Non current assets total 31.95M 35.71M 50.31M 43.27M 8.02M
Capital lease obligations 23.99M 27.41M 30.48M 32.64M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 87.20M -134.27M -45.66M -1.65M -0.13M
Change to liabilities -1.24M 13.70M 8.57M 1.69M 0.64M
Total cashflows from investing activities 87.20M -137.89M -45.66M -1.65M -0.13M
Net borrowings - - -0.06M -0.06M -0.06M
Total cash from financing activities 37.39M 157.82M 380.69M 19.99M 12.42M
Change to operating activities -4.14M -4.45M -3.46M -0.28M -0.03M
Net income -168.10M -149.29M -59.44M -14.86M -4.81M
Change in cash -29.05M -99.63M 288.52M 6.51M 12.42M
Begin period cash flow 203.52M 303.15M 14.63M 8.12M -4.30M
End period cash flow 174.47M 203.52M 303.15M 14.63M 8.12M
Total cash from operating activities -153.65M -119.56M -46.51M -11.83M -4.16M
Issuance of capital stock 36.86M 157.24M 381.17M 19.99M 7.42M
Depreciation 1.68M 1.09M 0.70M 0.27M 0.02M
Sale purchase of stock - - - 19.99M 7.42M
Other cashflows from financing activities 0.53M 0.58M 144.30M -1.65M 12.41M
Change to netincome 18.15M 19.38M 7.05M 1.35M 0.02M
Capital expenditures 3.07M 3.62M 1.16M 1.65M 0.13M
Change in working capital -5.38M 9.26M 5.11M 1.41M 0.60M
Stock based compensation 15.18M 17.54M 6.59M 0.03M 0.00M
Other non cash items 2.97M -0.75M 0.51M 1.32M 0.02M
Free cash flow -156.71M -123.18M -47.67M -13.48M -4.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
DYN
Dyne Therapeutics Inc		 0.07
0.39%		 17.99 - - - 2.01 -8.87
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Dyne Therapeutics Inc

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

1560 Trapelo Road, Waltham, MA, United States, 02451

781 786 8230

https://www.dyne-tx.com

192

Name Title Year Born
Mr. Joshua T. Brumm CEO, Pres & Director 1978
Ms. Susanna Gatti High M.B.A. Chief Operating Officer 1968
Dr. Oxana Beskrovnaya Ph.D. Chief Scientific Officer 1961
Dr. Romesh Subramanian Ph.D. Co-Founder & Advisor 1965
Mr. Gene Kim VP of Fin. 1977
Mr. Richard William Scalzo M.B.A. Sr. VP, Head of Fin. & Admin. and Treasurer 1986
Ms. Amy Reilly Sr. VP and Head of Corp. Communications & Investor Relations 1974
Ms. Kate Mitchell VP & Head of HR NA
Dr. Thomas-Christian Mix M.D., M.S. Sr. VP of Pharmacovigilance 1967
Ms. Debra Feldman Sr. VP & Head of Regulatory Affairs 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…